id: NEW:colistin_meropenem_combination_therapy_to_NEW:sofa_score
name: Colistin Plus Meropenem Combination Therapy â†’ Sequential Organ Failure Assessment
  Score
from_node:
  node_id: NEW:colistin_meropenem_combination_therapy
  node_name: Colistin Plus Meropenem Combination Therapy
to_node:
  node_id: NEW:sofa_score
  node_name: Sequential Organ Failure Assessment Score
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Administration of colistin plus meropenem combination therapy provides
  synergistic antimicrobial activity against multidrug-resistant gram-negative bacteria
  causing nosocomial pneumonia'
- 'Step 2: Enhanced bacterial killing through dual mechanisms - colistin disrupts
  bacterial cell membranes while meropenem inhibits cell wall synthesis, leading to
  more effective pathogen eradication'
- 'Step 3: Reduced bacterial load decreases systemic inflammatory response and prevents
  progression of sepsis-related organ dysfunction'
- 'Step 4: Improved infection control leads to stabilization and recovery of affected
  organ systems, resulting in lower Sequential Organ Failure Assessment (SOFA) scores
  indicating reduced multi-organ dysfunction'
evidence:
  quality_rating: B
  n_studies: 5
  primary_citation: Hazhir Moradi et al. 2024. Systematic review and meta-analysis
    of colistin plus meropenem therapy for the treatment of nosocomial pneumonia.
    Iranian journal of microbiology.
  supporting_citations: []
description: 'Colistin plus meropenem combination therapy significantly reduces Sequential
  Organ Failure Assessment (SOFA) scores in patients with nosocomial pneumonia compared
  to other colistin-based treatments. This meta-analysis of 5 studies involving 991
  patients demonstrated a statistically significant reduction in SOFA scores (OR =
  -0.28, 95% CI: -0.44 to -0.11, p = 0.001), indicating improved organ function with
  the combination therapy.'
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: -0.28
    type: standardized_mean_difference
    ci_lower: -0.44
    ci_upper: -0.11
  p_value: 0.001
  sample_size: 991
moderators:
- name: baseline_illness_severity
  direction: weakens
  strength: moderate
  description: Patients with higher baseline APACHE II scores may show less pronounced
    SOFA score improvements due to more severe underlying conditions
- name: comorbidity_burden
  direction: weakens
  strength: moderate
  description: Higher Charlson Comorbidity Index scores were associated with the treatment
    group, potentially affecting the magnitude of SOFA score reduction
